Clinical Trials
65 trialsMOMENTUM
AstraZeneca
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
ALLight
AstraZeneca
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
cAMeLot-1
Janssen Research & Development, LLC
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
AUGMENT-101
Syndax Pharmaceuticals
RELATIVITY-069
Bristol-Myers Squibb
A Study of BN104 in the Treatment of Acute Leukemia
Servier
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
MK-1045-002
MSD R&D (China) Co., Ltd.
TENACITY-01
BIOHENG THERAPEUTICS US LLC
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sanofi
First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies
Chimagen Biosciences, Ltd
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Beam Therapeutics Inc.
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
AbbVie
TBI-1501
Takara Bio Inc.
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Celgene
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Astex Pharmaceuticals, Inc.
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shenzhen TargetRx Co., Ltd.
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
AO GENERIUM
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TCR2 Therapeutics
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Atara Biotherapeutics
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Bellicum Pharmaceuticals
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Spectrum Pharmaceuticals, Inc
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Gilead Sciences
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
Gamida Cell ltd
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
Novartis
AMELIA
Autolus Limited
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Novartis
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
Novartis
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
Novartis
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
Gamida Cell ltd
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Mirror Biologics, Inc.
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Gilead Sciences
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Acrotech Biopharma Inc.
Phase I/II Study of DFP-10917 in Patients With Acute Leukemia
Delta-Fly Pharma, Inc.
CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
BSTPHASE1-01
BioSight Ltd.